Abstract
Dense gas techniques provide a suite of clean technology options for the processing of pharmaceuticals. Monodisperse, micron-sized particles can be produced at mild operating temperatures and with negligible solvent residue. In this study, protein was precipitated from organic solutions using dense carbon dioxide as antisolvent. The gas antisolvent precipitation process (GAS) was used to produce biologically active lysozyme, insulin, and myoglobin powders. The effects of operating temperature, solute concentration and the rate of antisolvent addition on the morphology, size, activity and residual solvent concentration of lysozyme and insulin precipitates have been examined. The powders produced consisted of uniformly sized non-aggregated spherical particles. Precipitate size was controlled between 0.05 µm and 2.0 µm by changes to the solvent and antisolvent compositions. In general the concentration of residual organic solvent was found to be dependent on the mass of antisolvent used during the washing cycle. Residual concentrations as low as 300 ppm were easily achievable in a single step. © 2000 Society of Chemical Industry
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Chemical Technology & Biotechnology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
